Table 5.
Response to Subcutaneous Alemtuzumab by Pretreatment Characteristics in Evaluable Patients
| Characteristic | No. of Patients |
Responders, % |
|---|---|---|
| No. of alemtuzumab courses | 29 | 79 |
| 1 | 22 | 86 |
| 2 | 7 | 57 |
| No. of prior treatments | 29 | 79 |
| 1 | 17 | 88 |
| 2 | 8 | 63 |
| ≥3 | 4 | 75 |
| IGHV | 23 | 83 |
| Mutated (<98% germline) | 9 | 89 |
| Unmutated (≥98% germline) | 14 | 79 |
| ZAP-70 | 21 | 76 |
| Negative (<20% of cells) | 11 | 91 |
| Positive (≥20% of cells) | 10 | 60 |
| CD38 | 26 | 81 |
| Negative (<30% of cells) | 12 | 75 |
| Positive (≥30% of cells) | 14 | 86 |
IGHV indicates immunoglobulin heavy chain variable region; ZAP-70, ζ chain-associated protein kinase 70; CD38, cluster of differentiation 38 (also known as cyclic adenine diphosphate ribose hydrolase).